Buprenorphine Induction Note (Office-Based or Home Induction)

Buprenorphine Induction – Problem-Oriented Clinical Note

Date: [date of encounter]

Time: [time]

Location: [clinic name / Telehealth]

Visit Type: [New / Established patient]

Induction Setting: [Office-based / Home induction]

Chief Concern

[Brief statement of visit purpose] (Keep concise and goal-focused, e.g., initiation of buprenorphine for OUD.)

HPI – OUD and Induction Readiness

[Patient goals and OUD history context] (Summarize prior MOUD trials, prior buprenorphine experience including any precipitated withdrawal, overdose history, relapse/return-to-use history.)

[Current opioid use pattern] (Document substance type, route, frequency, typical amount.) [Last opioid use details: substance, route, and exact date/time] (Safety-critical; if time is uncertain, explicitly document "unknown" and whether induction is being deferred or proceeding with rationale.) [Any recent long-acting opioid or methadone exposure] [Current withdrawal symptoms reported by patient] [Induction setting preference and reasoning]

Substance Use and Sedation Risk

• [Alcohol use pattern and last drink timing if relevant today]
• [Benzodiazepine or other sedative use: prescribed and non-prescribed, timing of last use] (Do not omit—affects monitoring requirements.)
• [Other substances used]
• [Past overdose history and current naloxone access]

Relevant Medical and Psychiatric History

• [Respiratory disease relevant to induction safety]
• [Hepatic impairment or relevant laboratory abnormalities]
• [Active psychiatric illness or suicidality]
• [Acute pain needs or upcoming procedures]
• [Current medications] (Highlight CNS depressants.)
• [Allergies/adverse reactions] (Note any buprenorphine or naloxone hypersensitivity.)

Pregnancy and Lactation Status

[Pregnancy status and test result if obtained] (Include only when applicable. If not obtained, document reason and plan. Note breastfeeding status and obstetric coordination if pregnant. May omit entirely if assessed and negative or not applicable.)

Vitals

BP: [value] HR: [value] RR: [value] SpO2: [value] Temp: [value]

(If telehealth/home and vitals not obtainable:) Vitals not obtained [telehealth / home induction]; patient denies severe symptoms; vitals to be obtained at follow-up visit.

Physical Exam

• [General appearance and distress level]
• [Pupils, rhinorrhea, lacrimation, yawning, piloerection, diaphoresis, tremor]
• [Mental status and sedation level]
• [Respiratory effort]

Withdrawal Assessment

COWS Score: [score] (List key contributing signs. If no formal score, document objective signs observed and clinical interpretation.)

Induction Readiness: [Patient is in mild / moderate / severe withdrawal and appropriate for induction today / Patient not yet in adequate withdrawal—induction deferred with instructions: (specify timing for reassessment and when to start)]

Data Reviewed

• PDMP: [date reviewed and notable findings]
• Urine toxicology: [key results / ordered, pending]
• Labs: [hepatic function, infectious disease screening as applicable] (If results pending: "Results pending; initiation not delayed; will review when available.")

Assessment

1. Opioid Use Disorder – [mild / moderate / severe] based on [criterion count or concise basis]; [actively using / early remission / sustained remission]
2. Withdrawal Status – [COWS score and/or objective signs summary]
3. Sedation and Overdose Risk Factors – [concurrent sedative or alcohol use; recent abstinence with tolerance loss; other risks]
4. Relevant Co-occurring Conditions – [psychiatric/medical issues affecting induction] (Omit if none.)

Induction Appropriateness: [Buprenorphine induction is appropriate; patient has confirmed OUD, can provide informed consent, and no contraindication identified today / Buprenorphine induction deferred due to (reason)]. [Office-based / Home] induction selected based on [patient preference / prior experience / work constraints / transportation / need for closer monitoring / other rationale].

Plan – Buprenorphine Induction

Informed Consent and Shared Decision-Making

[Discussed MOUD options (buprenorphine, methadone via OTP, naltrexone as appropriate); reviewed risks, benefits, and alternatives; answered questions. Patient consented to proceed with buprenorphine. Psychosocial services [accepted / offered and declined; MOUD initiated regardless with referrals offered].]

Induction Safety Checklist

• OUD diagnosis confirmed and patient goals established: [Met / Not Met]
• Last opioid use time documented: [Met / Not Met]
• Withdrawal adequate for induction (threshold: COWS ≥ [value] or objective signs): [Met / Not Met]
• Sedation screen completed: [Met / Not Met]
• PDMP reviewed: [Met / Not Met]
• Pregnancy status addressed (if applicable): [Met / Not Met / N/A]
• Naloxone plan addressed: [Met / Not Met]
• Safe medication storage discussed: [Met / Not Met]

(If any safety-critical item Not Met, document whether induction is deferred or modified and next steps.)

Induction Protocol

(Include only the section matching Induction Setting; omit the other.)

Office-Based Induction:

• [Baseline vitals and withdrawal score documented]
• [Initial observed dose: formulation, dose, time; sublingual technique confirmed]
• [Reassessment plan: timing, parameters assessed including sedation]
• [Criteria for additional dosing today versus holding]
• [Discharge criteria: stable vitals, no concerning sedation, improved withdrawal/cravings]
• [Post-discharge instructions: next dose timing, monitoring, clinic contact]

Home Induction:

• [Rationale patient appropriate for home induction: able to describe/rate withdrawal, understands instructions, reliable contact]
• [Self-assessment instructions: what adequate withdrawal should feel like before first dose]
• [Provider availability and contact method for phone consultation]
• [Red flag symptoms requiring urgent evaluation: severe vomiting/dehydration, chest pain, confusion, respiratory distress]
• [Follow-up requirement: date/time for check-in and visit]

Medication Plan

• Formulation: [Buprenorphine/naloxone / Buprenorphine monoproduct] (If monoproduct: rationale [pregnancy / allergy / methadone transition / other])
• Day 1: [initial dose], [dosing interval], [maximum daily dose]
• Day 2: [target total daily dose], [single vs divided dosing]
• Day 3 and stabilization: [target maintenance dose range and titration plan]
• Pharmacy: [confirmed availability / contingency plan]
• (If methadone/long-acting opioid transition: [extended washout plan and higher withdrawal threshold])
• (If fentanyl exposure suspected/confirmed: [precipitated withdrawal mitigation: higher COWS threshold, lower initial dose, closer reassessment; patient counseled on elevated risk])

(Dental care counseling provided: rinse mouth after medication dissolves, delay brushing at least 1 hour, maintain routine dental care.)

Supportive Medications

(Include only if prescribed; omit section if none.)

• [Alpha-2 agonist for autonomic symptoms: medication, dose, frequency]
• [Antiemetic: medication, dose, frequency]
• [Antidiarrheal: medication, dose, frequency]
• [Analgesic: medication, dose, frequency]
• [Sleep/anxiety support: medication, dose, frequency]

(If sedatives requested but not prescribed, document rationale: overdose risk with concurrent buprenorphine.)

Precipitated Withdrawal Counseling

[Patient counseled on: what precipitated withdrawal is and why it occurs; how to reduce risk (wait for adequate withdrawal, follow dosing schedule, do not take dose early); what to do if symptoms rapidly worsen after first dose (call clinic/after-hours line, do not take sedatives or alcohol, when to seek emergency care).]

Overdose Prevention and Naloxone

• Naloxone: [prescribed / provided / confirmed patient has supply]
• [Education provided on overdose recognition, response, and 911 activation]
• [Counseled on overdose risk from mixing with alcohol/sedatives and loss of tolerance if buprenorphine stopped]
• [Harm reduction counseling provided: fentanyl test strips, never use alone, other] (As locally appropriate.)

Co-occurring Conditions Management

(Include only if applicable; omit if no relevant co-occurring conditions.)

• [Psychiatric care coordination/referrals; suicidality safety plan if applicable]
• [Medical comorbidity management pertinent to induction safety]
• [Acute pain management strategy or peri-procedural planning]

Monitoring Plan

• Treatment agreement: [signed / deferred with plan]
• Urine drug testing: [baseline obtained/ordered; follow-up frequency]
• PDMP recheck: [cadence]
• Visit frequency: [early treatment schedule and criteria for extending intervals]
• [Safe storage reinforced and diversion prevention discussed]

Follow-Up

• [Next-day phone/video check-in: date/time] (If part of protocol.)
• [In-person or video visit within [X] days after induction / before next refill]
• [At follow-up assess: cravings, withdrawal control, adherence, side effects (sedation, oral health), ongoing substance use, mental health]
• [Urgent contact information provided for concerns before scheduled follow-up]

(For safety-critical fields—last opioid use time, withdrawal status, pregnancy when applicable, naloxone plan—if information is missing, document "unknown/not obtained" with reason and next steps. Omit non-critical details not collected. Do not infer unstated information.)